Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Sittig, Simone P ^a   Køllgaard, Tania ^a   Grønbæk, Kirsten ^b   Idorn, Manja ^a   Hennenlotter, Jörg ^c   Stenzl, Arnulf ^c   Gouttefangeas, Cécile ^c   Straten, Perthor ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clonally expanded T cells; Renal cell carcinoma; T cell phenotypes; T cell receptor clonotype mapping; Tumor infiltrating lymphocytes

Indexed keywords

CD8 ANTIGEN; CELL MARKER; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL SURFACE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOCYTE CLONE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; T LYMPHOCYTE;

EID: 84890285798     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26014     Document Type: Article

References (56)

1. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011; 104:741-5; PMID:21266975; http://dx.doi. org/10.1038/sj.bjc.6606061
2. George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011; 9:1011-8; PMID:21917625
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http:// dx.doi.org/10.1084/jem.20082492
5. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009; 157:9-19; PMID:19659765; http://dx.doi. org/10.1111/j.1365-2249.2009.03912.x
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133
9. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006; 107:46- 53; PMID:16708355; http://dx.doi.org/10.1002/cncr.21951
10. Stickel JS, Weinzierl AO, Hillen N, Drews O, Schuler MM, Hennenlotter J, Wernet D, Müller CA, Stenzl A, Rammensee HG, et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 2009; 58:1407- 17; PMID:19184600; http://dx.doi.org/10.1007/s00262-008-0655-6
11. Andersen MH, Becker JC, Straten Pt. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4:399-409; PMID:15864269; http://dx.doi.org/10.1038/nrd1717
12. Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006; 12:4163-70; PMID:16857787; http://dx.doi.org/10.1158/1078- 0432.CCR-05-2470
13. Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, et al. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 2008; 14:6916-23; PMID:18980986; http://dx.doi.org/10.1158/1078-0432.CCR-08-0466
14. Bernhard H, Maeurer MJ, Jäger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol 1996; 44:285-92; PMID:8795723; ht tp: //dx.doi.org/10.1046/j.1365-3083.1996. d01-304.x
15. ++ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19:990-9; PMID:21189474; http://dx.doi.org/10.1038/mt.2010.289
16. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007; 56:117-28; PMID:16676181; http://dx.doi.org/10.1007/s00262-006-0172-4
17. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. [epub ahead of print]. Nat Med 2012; 18; PMID:22842478; http://dx.doi. org/10.1038/nm.2883
18. Thor Straten P, Guldberg P, Grønbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol 1999; 163:443-7; PMID:10384147
19. thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer Immunol Immunother 1999; 48:386-95; PMID:10501852; http://dx.doi.org/10.1007/s002620050591
20. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153:2807-18; PMID:8077684
21. thor Straten P, Schrama D, Andersen MH, Becker JC. T cell clonotypes in cancer. J Transl Med. 2004; 2:11; PMID:15072580 ; http://dx.doi. org/10.1186/1479-5876-2-11
22. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69:8412-9; PMID:19843860; http://dx.doi.org/10.1158/0008-5472.CAN-09-0852
23. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9:4296-303; PMID:14555498
24. ++ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J Immunol 2007; 179:2368-79; PMID:17675498
25. Thor Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques 1998; 25:244-50; PMID:9714884
26. Miller KM, Ming TJ, Schulze AD, Withler RE. Denaturing gradient gel electrophoresis (DGGE): a rapid and sensitive technique to screen nucleotide sequence variation in populations. Biotechniques 1999; 27:1016-8, 1020-2, 1024 passim; PMID:10572650
27. Hadrup SR, Braendstrup O, Jacobsen GK, Mortensen S, Pedersen LO, Seremet T, Andersen MH, Becker JC, Straten PT. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer 2006; 119:831-8; PMID:16557580; http://dx.doi.org/10.1002/ijc.21894
28. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73A:975-83; PMID:18785267; http://dx.doi. org/10.1002/cyto.a.20643
29. Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, Kato Y, Fagarasan S, Muramatsu M, Eto T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 2011; 208:395-407; PMID:21300912; http://dx.doi.org/10.1084/jem.20100466
30. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
31. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, et al. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res 2009; 29:145-54; PMID:19331144
32. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239
33. Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61:5964-8; PMID:11507035
34. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006; 92:187-224; PMID:17145305; http://dx.doi. org/10.1016/S0065-2776(06)92005-7
35. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012; 72:1642-50; PMID:22311675; http://dx.doi. org/10.1158/0008-5472.CAN-11-2614
36. Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnölzer M, Warnken U, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, et al. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 2010; 120:2230-42; PMID:20458140; http://dx.doi.org/10.1172/JCI37646
37. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
38. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005; PMID:16648500; http://dx.doi.org/10.1200/JCO.2005.03.9594
39. +(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351
40. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, Toma H, Tanabe K. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97:780-6; PMID:16863511; http://dx.doi. org/10.1111/j.1349-7006.2006.00231.x
41. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847
42. + T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006; 176:2645-53; PMID:16456027
43. thor Straten P, Guldberg P, Andersen MH, Moerch U, Seremet T, Siedel C, et al. In situ cytokine therapy: Redistribution of clonally expanded therapeutic T-cell clones. Eur J Immunol 2001; 31:250-8; PMID:11265641; http://dx.doi. org/10.1002/1521-4141(200101)31:1250::AIDIMMU250 3.0.CO;2-8
44. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012; 23(Suppl 8):viii35-40; PMID:22918926; http://dx.doi.org/10.1093/annonc/mds261
45. Wang QJ, Hanada KI, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012; 72:6119-29; PMID:23071066; http://dx.doi. org/10.1158/0008-5472.CAN-12-0588
46. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012; 72:3664-76; PMID:22628427; http://dx.doi.org/10.1158/0008-5472.CAN-11-2791
47. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119:317-27; PMID:16482562; http://dx.doi.org/10.1002/ijc.21775
48. Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, Kato Y, Fagarasan S, Muramatsu M, Eto T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 2011; 208:395-407; PMID:21300912; http://dx.doi.org/10.1084/jem.20100466
49. Angevin E, Farace F, Genevée C, Henry-Amar M, Caignard A, Dietrich PY, Escudier B, Hercend T, Triebel F. Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. Int J Cancer 1993; 54:60-7; PMID:8478148; http://dx.doi.org/10.1002/ijc.2910540111
50. Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumorspecific cytotoxicity. Int J Cancer 1997; 72:431-40; PMID:9247286; http://dx.doi.org/10.1002/(SICI)1097-0215(19970729)72:3431: :AIDIJC10 3.0.CO;2-F
51. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 1996; 155:361-7; PMID:7490887; http://dx.doi.org/10.1016/S0022-5347(01)66661-8
52. ++PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother 2010; 33:956-64; PMID:20948441; http://dx.doi. org/10.1097/CJI.0b013e3181fad2b0
53. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 2009; 1:129-39; PMID:20445772; http://dx.doi.org/10.2217/1750743X.1.1.129
54. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi. org/10.1200/JCO.2009.26.7609
55. ++ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 2005; 19:2273-80; PMID:16304575; http://dx.doi.org/10.1038/sj.leu.2403972
56. thor Straten P, Kirkin AF, Siim E, Dahlström K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol 2000; 96:94-9; PMID:10900156; http://dx.doi. org/10.1006/clim.2000.4890